Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 225.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,010,758 shares of the company’s stock after buying an additional 700,458 shares during the period. Renaissance Technologies LLC owned 0.26% of Moderna worth $42,027,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB boosted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in Moderna in the 4th quarter worth about $37,000. Venturi Wealth Management LLC boosted its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in Moderna in the fourth quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $24.50 on Friday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The firm has a market cap of $9.47 billion, a PE ratio of -2.64 and a beta of 2.23. The company has a 50-day moving average of $31.72 and a two-hundred day moving average of $41.27.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. Citigroup assumed coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.